Navigation Links
IDRI and Zydus sign agreement for development of IDRI's vaccine candidate for visceral leishmaniasis
Date:7/25/2013

Seattle, WA, and Ahmedabad, India, July 25, 2013: In a unique partnership, Zydus, India's fourth largest healthcare group and an innovation-led global healthcare provider, and IDRI, a Seattle-based non-profit research and product development organization, announced today they are collaborating on the production and clinical development of IDRI's visceral leishmaniasis (VL) vaccine candidate, designed to prevent the deadly parasitic disease.

Known as Kala-Azar in India, VL is transmitted by the bite of an infected sand fly. There are over 500,000 new VL cases and 50,000 associated deaths each year. VL is the most severe form of leishmaniasis, affecting vital organs and, if left untreated, the disease can be fatal. A vaccine is considered essential to control and eliminate the disease. Currently, leishmaniasis occurs in four continents and is considered to be endemic in 88 countries; 72 of those are developing countries, with the disease being most common in India, Nepal, Bangladesh, Sudan and Brazil. While there are drugs to treat the disease, they are expensive and often toxic. To date, a safe and efficacious vaccine to prevent this disease does not exist.

Zydus and IDRI will collaborate to conduct clinical activities in India with the goal of developing, registering and marketing this vaccine candidate for the prevention of VL, while achieving the objective of global access that is, ensuring the vaccine is affordable to and accessible by all people in need. Conducting trials in India, where there are real-life situations of disease exposure, is critical to determining the effectiveness of the IDRI's VL vaccine candidate and ensuring it is approved and available within endemic countries.

IDRI's VL vaccine candidate, LEISH-F3+GLA-SE, is the product of more than 20 years of research and development supported by the U.S. National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation. The defined, purified, recombinant vacci
'/>"/>

Contact: Lee Schoentrup
lee.schoentrup@idri.org
206-858-6064
Infectious Disease Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Eurofins MWG Operon and Floragenex close co-marketing agreement for RAD discovery and RAD genotyping
2. Scripps Research announces research & license agreement with Janssen Pharmaceuticals
3. Sanford-Burnham Medical Research Institute and Mayo Clinic extend collaborative agreement
4. Psychemedics & TruTouch Announce US Sales/Marketing Distribution Agreement For TruTouch Technologies Rapid Optical Alcohol Detection & Biometric Test
5. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
6. University of Colorado and Orphan Technologies sign agreement
7. RayBiotech, Inc. Executes Neuroscience Biomarker Master Services Agreement with Banner Sun Health Research Institute
8. Ukraine, EU Advance on Visa Facilitation Agreement
9. CHOP and BGI strengthen partnership with agreement on pediatric brain tumor collaboration
10. Exclusive agreement to distribute Affinity Biosensors Archimedes system extends Malvern Instruments biopharma solutions
11. Wiley signs collaboration agreement with the Asian Federation of Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... bags could one day be made out of cocoa, ... now reporting. The novel process they developed and their ... agricultural and plastic waste problems, appear in the ACS ... Bayer and colleagues at the Italian Institute of Technology ... 2012, its production reached 288 million tons worldwide, but ...
(Date:8/20/2014)... When a colony of honeybees grows to about 4,000 ... reproductive cycle: the building of a special type of ... team of experts from the Department of Neurobiology and ... what starts the reproductive cycle of honeybee colonies. The ... The Science of Nature . , Reproduction isn,t ...
(Date:8/20/2014)... POINT ROBERTS, Washington , August 20, 2014 ... Addressing Security Concerns in the Payment Industry?   ... leading sectors including biometrics, issues commentary from analysts and experts ... Peaslee , Managing Partner at Thrive Analytics, Isabelle Moeller ... CEO of NXT-ID, Inc. (OTCBB: NXTD) ( OTCQB:NXTD ), a ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7
... the Institute for Stem Cell Biology and Medicine have demonstrated ... be genetically manipulated and coaxed to develop into mature T-cells, ... The study, to be published the week of July 3 ... Academy of Sciences, found that it is possible to convert ...
... skyrocketed from 497 cases reported in 1982 (the first year ... , Lyme disease, like other zoonoses, is ... a blood meal from a vertebrate host. In the eastern ... blacklegged ticks, Ixodes scapularis, which feed on a wide variety ...
... University of North Carolina at Chapel Hill has identified ... potentially dangerous interactions with certain medications. , For almost ... and pharmacists to avoid grapefruit juice if they are ... control blood pressure or lower cholesterol. Studies have shown ...
Cached Biology News:UCLA researchers develop T-cells from human embryonic stem cells 2A new view on Lyme disease: Rodents hold the key to annual risk 2A new view on Lyme disease: Rodents hold the key to annual risk 3Study identifies substances in grapefruit juice that interact dangerously with some drugs 2
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized and ... 29-30 in San Francisco, CA. This year’s conference brings ... and clinicians focused on addressing and solving the significant ... twelve years since the sequencing of the human genome, ... pharmacogenetic information in the label and molecular diagnostics have ...
(Date:8/20/2014)... your ear could improve the health of your heart, ... of Leeds used a standard TENS machine like those ... to the tragus, the small raised flap at the ... ear canal. , The stimulation changed the influence of ... nervous signals that can drive failing hearts too hard. ...
(Date:8/19/2014)... 20, 2014 One of the ... is an inadequate vascular supply. Nutrient and gas ... tissues is critical for successful regeneration and integration ... mitigate deficiencies in vascularization and promote angiogenesis in ... optimizing scaffold design and architecture, and enhancing scaffolds ...
(Date:8/19/2014)... Pa. , Aug. 19, 2014 A ... has been nominated for a Centers for Disease Control ... addressing a major public health concern. ... System, is one of a team of researchers nominated ... Charles C. Shepard Science Award for Data Methods and ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2'Tickling' your ear could be good for your heart 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... ZymoGenetics, Inc. (Nasdaq:,ZGEN) announced that the company ... update on the regulatory review of recombinant thrombin,(rThrombin). ... on August 22 at 5:00,p.m. Eastern Time by ... the call approximately 10 minutes prior to,the scheduled ...
... Missourians Introduce New Ballot Initiative to Pursue Cures for Patients, ... without involving controversial Human Cloning, WASHINGTON, Aug. ... Missouri to ensure that taxpayer funds,support cures for patients, without ... Research Council, issued the,following statement on the new initiative, Cures ...
... The U.S. Food and Drug,Administration (FDA) today approved ... ages 13-17 and for the short-term,treatment of bipolar ... I disorder in children and adolescents ages 10-17. ... more than 430 adolescents,ages 13-17, in the treatment ...
Cached Biology Technology:ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin 2FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania 2FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania 3
TEMPLIPHI HT SEQ AMPL KIT, 1 EA. Category: Sequencing Template Amplification....
This Malachite Green Phosphate Detection Kit...
Request Info...
1+ mg expected yield of purified protein, expressed in insect cells - excludes cDNA...
Biology Products: